[血清可溶性白细胞介素2受体（sIL-2R）水平在肾细胞癌患者中的作用]

[The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].

作者信息

Akiyama K, Tsuji M, Kurokawa Y, Yokota K, Kojima K, Naruo S, Kanayana H O, Kagawa S

机构信息

Department of Urology, School of Medicine, University of Tokushima.

出版信息

Nihon Hinyokika Gakkai Zasshi. 1997 Apr;88(4):473-8. doi: 10.5980/jpnjurol1989.88.473.

DOI:10.5980/jpnjurol1989.88.473

PMID:9155114

Abstract

PURPOSE

The correlation between the serum soluble interleukin-2 receptor (SIL-2R) levels and clinical stage is demonstrable in a variety of non-Hodgkin lymphomas. The prognostic significance of sIL-2R levels in the serum of patients with renal cell carcinoma (RCC) was investigated.

METHOD

sIL-2R were measured in patients with RCC (n=39) and normal control (n=6) by the enzyme immunoassay technique. Cases of RCC were classified according to the clinical stage, pathological grade and growth type. The IL-2R expression of RCC was evaluated by RT-PCR.

RESULT

The serum sIL-2R levels of patients with RCC showed significantly higher values than those of controls (p < 0.05). The serum sIL-2R levels in RCC were closely associated with the stage, grade and growth type of disease. The patients with high serum sIL-2R level (> = 1,000 U/L) exhibited a significantly poorer prognosis than those with low serum sIL-2R level (<1,000 U/L). The band of IL-R was detected only by using the template from the mRNA extracted from a resected tumor tissue of the RCC but not from the RCC cell lines.

CONCLUSION

It was suggested that the measurement of serum sIL-2R levels is useful for predicting the prognosis.

摘要

目的

血清可溶性白细胞介素-2受体（SIL-2R）水平与临床分期之间的相关性在多种非霍奇金淋巴瘤中是可证实的。本研究调查了肾细胞癌（RCC）患者血清中sIL-2R水平的预后意义。

方法

采用酶免疫测定技术检测39例RCC患者和6例正常对照者的sIL-2R。RCC病例根据临床分期、病理分级和生长类型进行分类。通过逆转录聚合酶链反应（RT-PCR）评估RCC的IL-2R表达。

结果

RCC患者的血清sIL-2R水平显著高于对照组（p<0.05）。RCC患者的血清sIL-2R水平与疾病的分期、分级和生长类型密切相关。血清sIL-2R水平高（>=1000 U/L）的患者预后明显比血清sIL-2R水平低（<1000 U/L）的患者差。仅使用从RCC切除的肿瘤组织中提取的mRNA模板检测到了IL-R条带，而从RCC细胞系中未检测到。